Fasinumab Biosimilar - Research Grade

Human

NGF

>1mg/ml

Human IgG4 S228P Kappa

Tanezumab Biosimilar - Research Grade (ICH5102), Fulranumab Biosimilar - Research Grade (ICH5157), Bedinvetmab Biosimilar - Research Grade (ICH5380), Izenivetmab Biosimilar - Research Grade (ICH5615), Luvagrobart Biosimilar - Research Grade (ICH5665), Ranevetmab Biosimilar - Research Grade (ICH5805)

https://www.imgt.org/mAb-DB/

ICH3002

P01138

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-NGF antibody fasinumab, engineered around human nerve growth factor (NGF, UniProt P01138) as its target. It is supplied for research use only and is not the clinical drug, nor intended for human or veterinary use. Built on a human IgG4 (S228P-stabilized) kappa framework, it reproduces the antigen-binding specificity of the originator against NGF, making it a convenient tool for interrogating NGF-driven signaling and for benchmarking assay performance. Typical research applications include use as a neutralizing reagent, a positive/reference control in binding and blocking assays, a capture or detection reagent in ligand-based ELISAs, and a comparator in biosimilarity or developability workflows. It is offered in low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) formats, and is available in bulk milligram-to-gram quantities to support in-vitro screening, cell-based assays, and preclinical model work where large, consistent lots are needed. Storage and handling follow standard antibody practice; buffer and formulation details are lot-specific. Nerve growth factor (NGF) is the prototypical neurotrophin, secreted as a precursor (proNGF) and processed to mature beta-NGF, which functions as a non-covalent homodimer. It signals through two receptors: the high-affinity receptor tyrosine kinase TrkA (NTRK1), driving neuronal survival, differentiation, and axonal growth via Ras/MAPK, PI3K/Akt, and PLC-gamma pathways; and the low-affinity p75 neurotrophin receptor (p75NTR/NGFR), which modulates affinity and can trigger apoptotic or survival signals depending on context. Beyond its classical role in sympathetic and sensory neuron development, NGF is a key mediator of peripheral pain sensitization and inflammatory hyperalgesia, acting on nociceptors and immune cells. Elevated NGF is implicated in chronic pain conditions such as osteoarthritis and chronic low back pain, which is why NGF neutralization has been pursued therapeutically. NGF is highly conserved across mammals.

Beta-NGF, Beta-nerve growth factor, NGFB

Detects human NGF

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.